FAKTOR-OPTIONSSCHEIN - ZEALAND PHARMA | Market Closed - Börse Stuttgart 07:58:34 2024-05-27 am EDT | ||
| 84.86 EUR | +21.77% |
|
| Current month | -13.48% | ||
| 1 month | -14.00% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ZEALAND PHARMA A/S
Latest news about ZEALAND PHARMA A/S
More news
| Date | Price | Change |
|---|---|---|
| 24-05-27 | 84.86 | +21.77% |
| 24-05-24 | 69.69 | -23.24% |
| 24-05-23 | 90.79 | +1.58% |
| 24-05-22 | 89.38 | -7.18% |
| 24-05-21 | 96.29 | +20.54% |
Delayed Quote Börse Stuttgart
Last update May 27, 2024 at 07:58 am EDT
More quotesStatic data
| Product type | Exotic Products |
|---|---|
| Buy / Sell | CALL |
| Underlying | ZEALAND PHARMA A/S |
| Issuer | Morgan Stanley |
| WKN | MB1CZN |
| ISIN | DE000MB1CZN6 |
| Date issued | 2022-12-12 |
| Strike | 440.1 kr |
| Maturity | Unlimited |
| Parity | 0.27 : 1 |
| Emission price | 10 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 257.8 € |
|---|---|
| Lowest since issue | 5.45 € |
| Spread | 4.99 € |
| Spread % | 5.73% |
Company Profile
Zealand Pharma A/S is specialized in the research and development of peptide drugs mainly for the treatment of diabetes, rare diseases and obesity.
At the end of 2022, the Group had a portfolio of 7 products in clinical development (including 2 in phase III, 3 in phase II and 2 in phase I), and 4 products in preclinical development.
Sector
-
Consensus: Zealand Pharma A/S
Sell
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
617
DKK
Average target price
785.6
DKK
Spread / Average Target
+27.32%
- Stock Market
- Certificates
- Certificat
